EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Sodium–glucose cotransporter 2 inhibitor therapy reduces the administration frequency of steroid injection in patients with diabetic macular edema: A cohort study using the Japanese health insurance claims database

Ryoichi Ishibashi iD, Masaya Koshizaka iD, Yoko Takatsuna, Tomoaki Tatsumi, Yoshiro Maezawa, Yuki Shiko, Yosuke Inaba, Yohei Kawasaki, Yusuke Kashiwagi, Eiryo Kawakami, Shuichi Yamamoto, Koutaro Yokote

Journal of Diabetes Investigation · 2024

DOI: 10.1111/jdi.14253 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Diabetes Investigation, 2024. Verfasst von Ryoichi Ishibashi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Japan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Macular Edema, Diabetic Retinopathy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Introduction Severe diabetic macular edema (DME) is often resistant to anti‐vascular endothelial growth factor therapy. Steroids are particularly effective at reducing edema by suppressing inflammation; they are also used as an alternative to expensive anti‐vascular endothelial growth factor therapy in some patients. Therefore, the use of steroids in DME reflects an unmet need for anti‐vascular endothelial growth factor therapy. Notably, triamcinolone acetonide (TA) injections are widely used in Japan. Here, we evaluated the frequency of TA as an indicator of the efficacy of sodium–glucose cotransporter 2 inhibitors (SGLT2is) in DME treatment using a health insurance claims database. Materials and Methods In this cohort study, we retrospectively analyzed the health insurance claims data of 11 million Japanese individuals from 2005 to 2019. The frequency and duration of TA injection after the initiation of SGLT2is or other antidiabetic drugs were analyzed.

Results

Among the 2,412 matched patients with DME, the incidence rate of TA injection was 63.8 times per 1,000 person‐years in SGLT2i users and 94.9 times per 1,000 person‐years in non‐users. SGLT2is reduced the risk for the first ( P = 0.0024, hazard ratio 0.66, 95% confidence interval 0.50–0.87), second ( P = 0.0019, hazard ratio 0.53, 95% confidence interval 0.35–0.80) and third TA ( P = 0.0053, hazard ratio 0.44, 95% confidence interval 0.25–0.80) injections. A subanalysis of each baseline characteristic of the patients showed that SGLT2is were effective regardless of the background factors.

Conclusions

The use of SGLT2is reduced the frequency of TA injection in patients with DME. Therefore, SGLT2i therapy might be a novel, noninvasive and low‐cost adjunctive therapy for DME.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsMacular EdemaDiabetic RetinopathyHumansMaleFemaleJapanRetrospective StudiesMiddle AgedAgedDatabases, FactualTriamcinolone AcetonideFollow-Up StudiesCohort StudiesInsurance, HealthEast Asian People

Stichwörter der Autor:innen

Diabetic macular edemaSodium–glucose cotransporter 2 inhibitorSteroid injection

Substanzen

Sodium-Glucose Transporter 2 InhibitorsTriamcinolone Acetonide

Autor:innen und Institutionen

  • Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Japan.
  • Department of Endocrinology, Hematology, and Gerontology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Center for Preventive Medical Sciences, Chiba University, Chiba, Japan.
  • Department of Ophthalmology, Chiba Rosai Hospital, Ichihara, Japan.
  • Department of Ophthalmology and Vision Science, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Clinical Research Center, Chiba University Hospital, Chiba, Japan.

ORCID-Profile: Ryoichi Ishibashi, Masaya Koshizaka

Förderung

  • Astellas Pharma

Zitieren

APA

Ishibashi, R., Koshizaka, M., Takatsuna, Y., Tatsumi, T., Maezawa, Y., Shiko, Y., Inaba, Y., Kawasaki, Y., Kashiwagi, Y., Kawakami, E., Yamamoto, S., & Yokote, K. (2024). Sodium–glucose cotransporter 2 inhibitor therapy reduces the administration frequency of steroid injection in patients with diabetic macular edema: A cohort study using the Japanese health insurance claims database. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14253

Vancouver

Ishibashi R, Koshizaka M, Takatsuna Y, Tatsumi T, Maezawa Y, Shiko Y, et al. Sodium–glucose cotransporter 2 inhibitor therapy reduces the administration frequency of steroid injection in patients with diabetic macular edema: A cohort study using the Japanese health insurance claims database. Journal of Diabetes Investigation. 2024. doi:10.1111/jdi.14253

BibTeX
@article{Ishibashi2024,
  author = {Ishibashi, Ryoichi and Koshizaka, Masaya and Takatsuna, Yoko and Tatsumi, Tomoaki and Maezawa, Yoshiro and Shiko, Yuki and Inaba, Yosuke and Kawasaki, Yohei and Kashiwagi, Yusuke and Kawakami, Eiryo and Yamamoto, Shuichi and Yokote, Koutaro},
  title = {Sodium–glucose cotransporter 2 inhibitor therapy reduces the administration frequency of steroid injection in patients with diabetic macular edema: A cohort study using the Japanese health insurance claims database},
  journal = {Journal of Diabetes Investigation},
  year = {2024},
  doi = {10.1111/jdi.14253}
}
Kostenlos starten →